Clinical Trials in San Antonio

Showing 8321-8340 of 14,633 trials

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086

This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

Hypertension

Novartis Pharmaceuticals19 participantsStarted May 2011

Anaheim, California, United States • Fort Myers, Florida, United States • Miramar, Florida, United States +8 more locations

COMPLETEDPhase 1/2< 1 mile

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

Relapsed or Refractory Multiple Myeloma

Novartis Pharmaceuticals29 participantsStarted Jul 2008

Scottsdale, Arizona, United States • San Antonio, Texas, United States • Melbourne, Australia +6 more locations

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Find Trials by Condition in San Antonio

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

The CDR Implementation Trial

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Evaluation of Biomarkers of Traumatic Brain Injury

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors